Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 40

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 40
---
 in the household of a director, director nominee, executive officer or holder of 5% or more of our voting stock.
After its review, the Audit Committee may approve or ratify the transaction.

Other than as disclosed below, and except for
the regular salary and bonus payments made to our directors and officers in the ordinary course of business as described in the section
“Executive Compensation,” there have been no transactions since January 1, 2023 or any currently proposed transaction
or series of similar transactions to which the Company was or is to be a party, in which the amount involved exceeds USD$120,000 and in
which any current or former director or officer of the Company, any 5% or greater stockholder of the Company or any member of the immediate
family of any such persons had or will have a direct or indirect material interest.

<div align='center'>23

PROPOSAL 2</div>

APPROVAL OF AN AMENDMENT TO INCREASE THE NUMBER OF AUTHORIZED SHARES UNDER THE 2022 EQUITY INCENTIVE PLAN BY 250,000 SHARES

Our Board has adopted a resolution declaring it
advisable and in the best interests of the Company and its stockholders that the shares of common stock authorized for issuance under
the 2022 Plan be increased by 250,000 (the “Plan Amendment”).

On November 22, 2022,
our Board and our stockholders approved the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The 2022 Plan governs equity
awards to our employees, directors, officers, consultants and other eligible participants. Initially, the maximum number of shares of
our common stock that may be subject to awards under the 2022 Plan was equal to 3,977. The 2022 Plan provides for an annual automatic
increase in the number of shares available for issuance beginning on January 1, 2023, and each January 1 thereafter, by four percent (4%)
of the number of outstanding shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined
by our Board. As of the Record Date, the maximum shares of our common stock that may be subject to awards under the 2022 Plan is equal
to 215,452.

The purpose of the 2022
Plan is to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive
to employees, directors and consultants